Purixan

Description

Mercaptopurine, a nucleoside metabolic inhibitor, known chemically as 1,7-dihydro-6H-purine-6-thione monohydrate, is an analogue of the purine bases adenine and hypoxanthine. Mercaptopurine is a yellow, odorless or practically odorless, crystalline powder with a molecular formula of C₅H₄N₄S·H₂O and a molecular weight of 170.20 as a monohydrate. The structural formula is:

 

 

PURIXAN (mercaptopurine) oral suspension is supplied for oral administration and contains 2000 mg/100 mL (20 mg/mL) of mercaptopurine. The suspension also contains the following inactive ingredients: xanthan gum, aspartame, concentrated raspberry juice, sucrose, ethyl parahydroxybenzoate sodium, methyl parahydroxybenzoate sodium, potassium sorbate, sodium hydroxide and purified water. PURIXAN is a pink to brown viscous suspension. In addition, a press-in bottle adapter and two oral dispensing syringes (one 1 mL and one 5 mL) are provided.

Indications

Acute Lymphoblastic Leukemia

PURIXAN is indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Dosage And Administration

Recommended Dosage

The recommended starting dose of PURIXAN is 1.5 to 2.5 mg/kg (50 to 75 mg/m²) orally once daily as part of combination chemotherapy maintenance regimen. Take PURIXAN either consistently with or without food.

After initiating PURIXAN, monitor complete blood counts (CBC) and adjust the dose to maintain absolute neutrophil count (ANC) at a desirable level and for excessive myelosuppression. Evaluate the bone marrow in patients with prolonged myelosuppression or repeated episodes of myelosuppression to assess leukemia status and marrow cellularity.

Evaluate thiopurine S-methyltransferase (TPMT) and nucleotide diphosphatase (NUDT15) status in patients in patients with severe myelosuppression or repeated episodes of myelosuppression [see Dosage Modifications In Patients With TPMT And NUDT15 Deficiency].

If a patient misses a dose, instruct the patient to continue with the next scheduled dose.

Dosage Modifications In Patients With TPMT And NUDT15 Deficiency

Consider testing for TPMT and NUDT15 deficiency in patients who experience severe myelosuppression or repeated episodes of myelosuppression [see WARNINGS AND PRECAUTIONS, CLINICAL PHARMACOLOGY].

Homozygous Deficiency In Either TPMT Or NUDT15

Patients with homozygous deficiency of either enzyme typically require 10% or less of the recommended dosage. Reduce the recommended starting dosage of PURIXAN in patients who are known to have homozygous TPMT or NUDT15 deficiency.

Heterozygous Deficiency In TPMT And/Or NUDT15

Reduce the PURIXAN dosage based on tolerability. Most patients with heterozygous TPMT or NUDT15 deficiency tolerate recommended dosage, but some require dose reduction based on adverse reactions. Patients who are heterozygous for both TPMT and NUDT15 may require more substantial dose reductions.

Dosage Modifications In Renal And Hepatic Impairment

Renal Impairment

Use the lowest recommended starting dosage for PURIXAN in patients with renal impairment (CLcr less than 50 mL/min). Adjust the dosage to maintain absolute neutrophil count (ANC) at a desirable level and for adverse reactions [see Uses In Specific Populations].

Hepatic Impairment

Use the lowest recommended starting dosage for PURIXAN in patients with hepatic impairment. Adjust the dosage to maintain absolute neutrophil count (ANC) at a desirable level and for adverse reactions [see Uses In Specific Populations].

Dosage Modification With Concomitant Use Of Allopurinol

Reduce the dose of PURIXAN to one-third to one-quarter of the current dosage when coadministered with allopurinol [see DRUG INTERACTIONS].

Administration

Shake the bottle vigorously for at least 30 seconds to ensure the oral suspension is well mixed. PURIXAN is a pink to brown viscous oral suspension.

Provide a press-in bottle adapter and two oral dispensing syringes (one 1 mL and one 5 mL).

Train patients or caregivers on proper handling, storage, administration, disposal and clean-up of accidental spillage prior to initiation of PURIXAN and during each visit to the clinic.

Advise patients and caregivers to use PURIXAN within 8 weeks and properly discard remaining PURIXAN after 8 weeks.

Provide instructions regarding which syringe to use and how to administer the specified dose, since PURIXAN is supplied with 1 mL and 5 mL oral dispensing syringes.

Advise patients that the oral dispensing syringe is intended for multiple uses and provide the following instructions:

• Wash the oral dispensing syringe with warm ‘soapy’ water and rinse well;
• Hold the oral dispensing syringe under water and move the plunger up and down several times to make sure the inside of the oral dispensing syringe is clean;
• Ensure the oral dispensing syringe is completely dry before use of the oral dispensing syringe again; and
• Store the oral dispensing syringe in a hygienic place with PURIXAN.

PURIXAN is a cytotoxic drug. Follow special handling and disposal procedures.¹

How Supplied

Dosage Forms And Strengths

Oral Suspension

2000 mg/100 mL (20 mg/mL) pink to brown in color.

Storage And Handling

PURIXAN (mercaptopurine) oral suspension is supplied as 2000 mg/100 mL (20 mg/mL) pink to brown viscous liquid in amber glass multiple-dose bottles. In addition, a press-in bottle adapter and two oral dispensing syringes (one 1 mL and one 5 mL) are provided.

Each carton NDC 62484-0020-2 contains 1 bottle of PURIXAN NDC 62484-0020-1.

• Store PURIXAN between 59°F to 77°F (15°C to 25°C). Store in a dry place.

PURIXAN is a cytotoxic drug. Follow special handling and disposal procedures¹.

REFERENCES

1. OSHA Hazardous Drugs. OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html

Manufactured by: Nova Laboratories, Ltd Leicester LE18 4YL United Kingdom. Revised: April 2020

The following clinically significant adverse reactions are described elsewhere in the labeling:

• Myelosuppression [see WARNINGS AND PRECAUTIONS]
• Hepatotoxicity [see WARNINGS AND PRECAUTIONS]
• Immunosuppression [see WARNINGS AND PRECAUTIONS]
• Treatment Related Malignancies [see WARNINGS AND PRECAUTIONS]
• Macrophage Activation Syndrome [see WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Based on multicenter cooperative group ALL trials, the most common adverse reaction occurring in > 20% of patients was myelosuppression, including anemia, neutropenia, lymphopenia and thrombocytopenia. Adverse reactions occurring in 5% to 20 % of patients included anorexia, nausea, vomiting, diarrhea, malaise, and rash. Adverse reactions occurring in < 5 % of patients included urticaria, hyperuricemia, oral lesions, elevated transaminases, hyperbilirubinemia, hyperpigmentation, infections, and pancreatitis. Oral lesions resemble thrush rather than antifolic ulcerations. Delayed or late toxicities include hepatic fibrosis, hyperbilirubinemia, alopecia, pulmonary fibrosis, oligospermia and secondary malignancies [see WARNINGS AND PRECAUTIONS].

Drug fever has been reported with PURIXAN.

Postmarketing Experience

The following adverse reactions have been identified during postapproval use of PURIXAN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions include: photosensitivity, hypoglycemia, and portal hypertension.

Allopurinol

Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions [see WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS]. Reduce the dose of PURIXAN when coadministered with allopurinol [see DOSAGE AND ADMINISTRATION].

Warfarin

The coadministration of PURIXAN with warfarin may decrease the anticoagulant effectiveness of warfarin. Monitor the international normalized ratio (INR) in patients receiving warfarin and adjust the warfarin dosage as appropriate.

Myelosuppressive Products

PURIXAN can cause myelosuppression. Myelosuppression may be increased when PURIXAN is coadministered with other drugs that cause myelosuppression. Enhanced myelosuppression has been noted in some patients receiving trimethoprim-sulfamethoxazole. Monitor the CBC and adjust the dose of PURIXAN for excessive myelosuppression [see DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS].

Aminosalicylates

Aminosalicylates (e.g., mesalamine, olsalazine or sulfasalazine) may inhibit the TPMT enzyme, which may increase the risk of myelosuppression when coadministered with PURIXAN. When aminosalicylates and PURIXAN are coadministered, use the lowest possible doses for each drug and monitor more frequently for myelosuppression [see WARNINGS AND PRECAUTIONS].

Hepatotoxic Products

PURIXAN can cause hepatotoxicity. Hepatotoxicity may be increased when PURIXAN is coadministered with other products that cause hepatotoxicity. Monitor liver tests more frequently in patients who are receiving PURIXAN with other hepatotoxic products [see WARNINGS AND PRECAUTIONS].

WarningS

Included as part of the “PRECAUTIONS” Section

Precautions

Myelosuppression

The most consistent, dose-related adverse reaction of PURIXAN is myelosuppression, manifested by anemia, leukopenia, thrombocytopenia, or any combination of these. Monitor CBC and adjust the dosage of PURIXAN for excessive myelosuppression [see DOSAGE AND ADMINISTRATION].

Consider testing for thiopurine S-methyltransferase (TPMT) or nucleotide diphosphatase (NUDT15) deficiency in patients with severe myelosuppression or repeated episodes of myelosuppression. TPMT genotyping or phenotyping (red blood cell TPMT activity) and NUDT15 genotyping can identify patients who have reduced activity of these enzymes. Patients with homozygous TPMT or NUDT15 deficiency may require a dose reduction [see DOSAGE AND ADMINISTRATION, CLINICAL PHARMACOLOGY].

Myelosuppression can be exacerbated by coadministration with allopurinol, aminosalicylates or other products that cause myelosuppression [see DRUG INTERACTIONS]. Reduce the dosage of PURIXAN when coadministered with allopurinol [see DOSAGE AND ADMINISTRATION].

Hepatotoxicity

Mercaptopurine is hepatotoxic. There are reports of deaths attributed to hepatic necrosis associated with the administration of mercaptopurine. Hepatic injury can occur with any dosage but seems to occur with greater frequency when the recommended dosage is exceeded. In some patients, jaundice has cleared following withdrawal of mercaptopurine and reappeared with rechallenge.

Usually, clinically detectable jaundice appears early in the course of treatment (1 to 2 months); however, jaundice has been reported as early as 1 week and as late as 8 years after starting mercaptopurine. The hepatotoxicity has been associated in some cases with anorexia, diarrhea, jaundice and ascites. Hepatic encephalopathy has occurred.

Monitor serum transaminase levels, alkaline phosphatase, and bilirubin levels at weekly intervals when first beginning therapy and at monthly intervals thereafter. Monitor liver tests more frequently in patients who are receiving PURIXAN with other hepatotoxic drugs [see DRUG INTERACTIONS] or with known pre-existing liver disease. Withhold PURIXAN at onset of hepatotoxicity.

Immunosuppression

Mercaptopurine is immunosuppressive and may impair the immune response to infectious agents or vaccines. Due to the immunosuppression associated with maintenance chemotherapy for ALL, response to all vaccines may be diminished and there is a risk of infection with live virus vaccines. Consult immunization guidelines for immunocompromised patients.

Treatment Related Malignancies

Hepatosplenic T-cell lymphoma has been reported in patients treated with mercaptopurine for inflammatory bowel disease (IBD), an unapproved use. Mercaptopurine is mutagenic in animals and humans, carcinogenic in animals, and may increase the risk of secondary malignancies.

Patients receiving immunosuppressive therapy, including mercaptopurine, are at an increased risk of developing lymphoproliferative disorders and other malignancies, notably skin cancers (melanoma and non-melanoma), sarcomas (Kaposi’s and non-Kaposi’s) and uterine cervical cancer in situ. The increased risk appears to be related to the degree and duration of immunosuppression. It has been reported that discontinuation of immunosuppression may provide partial regression of the lymphoproliferative disorder.

A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. A combination of multiple immunosuppressants, given concomitantly increases the risk of Epstein-Barr virus (EBV)-associated lymphoproliferative disorders.

Macrophage Activation Syndrome

Macrophage activation syndrome (MAS) (hemophagocytic lymphohistiocytosis) is a known, life-threatening disorder that may develop in patients with autoimmune conditions, in particular with inflammatory bowel disease (IBD), and there could potentially be an increased susceptibility for developing the condition with the use of mercaptopurine (an unapproved use). If MAS occurs, or is suspected, discontinue PURIXAN. Monitor for and promptly treat infections such as EBV and cytomegalovirus (CMV), as these are known triggers for MAS.

Embryo-Fetal Toxicity

PURIXAN can cause fetal harm when administered to a pregnant woman. An increased incidence of miscarriage has been reported in women who received mercaptopurine in the first trimester of pregnancy. Adverse embryo-fetal findings, including miscarriage and stillbirth, have been reported in women who received mercaptopurine after the first trimester of pregnancy. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with PURIXAN and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with PURIXAN and for 3 months after the last dose [see Use In Specific Populations].

Patient Counseling Information

Advise the patients and caregivers to read the FDA-approved patient labelling (PATIENT INFORMATION and Instructions for Use).

Major Adverse Reactions

Advise patients and caregivers that PURIXAN can cause myelosuppression, hepatotoxicity, and gastrointestinal toxicity. Advise patients to contact their healthcare provider if they experience fever, sore throat, jaundice, nausea, vomiting, signs of local infection, bleeding from any site, or symptoms suggestive of anemia [see WARNINGS AND PRECAUTIONS].

Proper Preparation And Administration

Advise patients or caregivers on proper handling, storage, preparation, administration, and disposal and clean-up of accidental spillage of the medication prior to initiation and on each visit to the clinic [see DOSAGE AND ADMINISTRATION].

Embryo-Fetal Toxicity

• Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see WARNINGS AND PRECAUTIONS, Use In Specific Populations].
• Advise females of reproductive potential to use effective contraception during treatment with PURIXAN and for 6 months after the last dose [see Use In Specific Populations].
• Advise males with female partners of reproductive potential to use effective contraception during treatment with PURIXAN and for 3 months after the last dose [see Use In Specific Populations, Nonclinical Toxicology].

Lactation

Advise women not to breastfeed during treatment with PURIXAN and for 1 week after the last dose [see Use In Specific Populations].

Infertility

Advise males and females of reproductive potential that PURIXAN can impair fertility [see Use In Specific Populations].

Other Adverse Reactions

Instruct patients to minimize sun exposure due to risk of photosensitivity [see ADVERSE REACTIONS].

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment Of Fertility

Mercaptopurine is carcinogenic in animals.

Mercaptopurine causes chromosomal aberrations in cells derived from animals and humans and induces dominant-lethal mutations in the germ cells of male mice.

Mercaptopurine can impair fertility. In mice, surviving female offspring of mothers who received chronic low doses of mercaptopurine during pregnancy were found sterile, or if they became pregnant, had smaller litters and more dead fetuses as compared to control animals.

Use In Specific Populations

Pregnancy

Risk Summary

PURIXAN can cause fetal harm when administered to a pregnant woman [see CLINICAL PHARMACOLOGY]. Pregnant women who receive mercaptopurine have an increased incidence of miscarriage and stillbirth (see Data). Advise pregnant women of the potential risk to a fetus.

The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Human Data

Women receiving mercaptopurine in the first trimester of pregnancy have an increased incidence of miscarriage; the risk of malformation in offspring surviving first trimester exposure is not known. In a series of 28 women receiving mercaptopurine after the first trimester of pregnancy, 3 mothers died prior to delivery, 1 delivered a stillborn child, and 1 aborted; there were no cases of macroscopically abnormal fetuses.

Animal Data

Mercaptopurine was embryo-lethal and teratogenic in several animal species (rat, mouse, rabbit, and hamster) at doses less than the recommended human dose.

Lactation

Risk Summary

There are no data on the presence of mercaptopurine or its metabolites in human milk, the effects on the breastfed child or the effects on milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with PURIXAN and for 1 week after the last dose.

Females And Males Of Reproductive Potential

PURIXAN can cause fetal harm when administered to pregnant women [see Pregnancy].

Pregnancy Testing

Verify the pregnancy status in females of reproductive potential prior to initiating PURIXAN [see Pregnancy].

Contraception

Females

Advise females of reproductive potential to use effective contraception during treatment with PURIXAN and for 6 months after the last dose.

Males

Based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with PURIXAN and for 3 months after the last dose [see Nonclinical Toxicology].

Infertility

Females and Males

Based on findings from animal studies, PURIXAN can impair female and male fertility [see Nonclinical Toxicology]. The long-term effects of mercaptopurine on female and male fertility, including the reversibility have not been studied.

Pediatric Use

Safety and effectiveness of PURIXAN has been established in pediatric patients. Use of PURIXAN in pediatrics is supported by evidence from the published literature and clinical experience. Symptomatic hypoglycemia has been reported in pediatric patients with ALL receiving mercaptopurine. Reported cases were in pediatrics less than 6 years or with a low body mass index.

Geriatric Use

Clinical studies of mercaptopurine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or another drug therapy.

Renal Impairment

Use the lowest recommended starting dosage for PURIXAN or increase the dosing interval to every 36 to 48 hours in patients with renal impairment (CLcr less than 50 mL/min). Adjust the dose to maintain absolute neutrophil count (ANC) at a desirable level and for adverse reactions [see DOSAGE AND ADMINISTRATION].

Hepatic Impairment

Use the lowest recommended starting dosage for PURIXAN in patients with hepatic impairment. Adjust the dose to maintain absolute neutrophil count (ANC) at a desirable level and for adverse reactions [see DOSAGE AND ADMINISTRATION].

Overdose

Signs and symptoms of mercaptopurine overdosage may be immediate (anorexia, nausea, vomiting, and diarrhea) or delayed (myelosuppression, liver dysfunction, and gastroenteritis). Dialysis cannot be expected to clear mercaptopurine. Hemodialysis is thought to be of marginal use due to the rapid intracellular incorporation of mercaptopurine into active metabolites with long persistence.

Withhold PURIXAN immediately if severe or life-threatening adverse reactions occur during treatment. If a patient is seen immediately following an accidental overdosage, it may be useful to induce emesis.

Contraindications

None.

Mechanism Of Action

Mercaptopurine is a purine analog that undergoes intracellular transport and activation to form metabolites including thioguanine nucleotides (TGNs). Incorporation of TGNs into DNA or RNA results in cell-cycle arrest and cell death. TGNs and other mercaptopurine metabolites are also inhibitors of de novo purine synthesis and purine nucleotide interconversions. Mercaptopurine was cytotoxic to proliferating cancer cells in vitro and had antitumor activity in mouse tumor models. It is not known which of the biochemical effects of mercaptopurine and its metabolites are directly or predominantly responsible for cell death.

Pharmacodynamics

Exposure-Response Relationships

Mercaptopurine exposure-response relationships and the time course of pharmacodynamics response are unknown.

Pharmacokinetics

Following a single oral dose of PURIXAN 50 mg under fasted conditions to adult healthy subjects, the median (min – max) AUC0-INF was 137 h•ng/mL (77 – 268 h•ng/mL) and Cmax was 93 ng/mL (40 – 204 ng/mL).

Absorption

PURIXAN is absorbed after oral administration with a median (min – max) Tmax of 0.75 (0.33 – 2.5) hours.

Effect of Food

Food has been shown to decrease the exposure of mercaptopurine.

Distribution

The volume of distribution exceeds total body water with a mean volume of distribution of approximately 0.9 L/kg. There is negligible entry of mercaptopurine into cerebrospinal fluid.

Plasma protein binding averages 19% over the concentration range 10 to 50 mcg/L.

Elimination

The median (min – max) elimination half-life (t_1/2) was 1.3 (0.9 – 5.4) hours.

Metabolism

Mercaptopurine is inactivated via two major pathways. One is thiol methylation, which is catalyzed by the polymorphic enzyme thiopurine S-methyltransferase (TPMT), to form the inactive metabolite methylmercaptopurine. The second inactivation pathway is oxidation, which is catalyzed by xanthine oxidase. The product of oxidation is the inactive metabolite 6-thiouric acid.

Elimination

After oral administration of mercaptopurine, urine contains intact mercaptopurine, thiouric acid (formed by direct oxidation by xanthine oxidase, probably via 6-mercapto-8-hydroxypurine), and a number of 6-methylated thiopurines. In one subject, a total of 46% of the dose could be accounted for in the urine (as parent drug and metabolites) in the first 24 hours.

Specific Populations

Pediatric Patients

Wide inter individual variations in systemic exposure is observed. Following oral administration of 50 mg/m² mercaptopurine in 10 children, median plasma concentrations 1 hour post dose was 0.35 (range 0.03 to 1.03) μM and median AUC1–5hours was 56 (range 23 to 65) μM·min. Tmax ranged from 1 to 3 hours.

Pharmacogenomics

Several published studies indicate that patients with reduced TPMT or NUDT15 activity receiving usual doses of mercaptopurine, accumulate excessive cellular concentrations of active 6-TGNs, and are at higher risk for severe myelosuppression [see WARNINGS AND PRECAUTIONS]. In a study of 1028 children with ALL, the approximate tolerated mercaptopurine dosage for patients with TPMT and/or NUDT15 deficiency on mercaptopurine maintenance therapy (as a percentage of the planned dosage) was as follows: heterozygous for either TPMT or NUDT15, 50-90%; heterozygous for both TPMT and NUDT15, 30-50%; homozygous for either TPMT or NUDT15, 5-10%.

Approximately 0.3% (1:300) of patients of European or African ancestry have two loss-of-function alleles of the TPMT gene and have little or no TMPT activity (homozygous deficient or poor metabolizers), and approximately 10% of patients have one loss-of-function TPMT allele leading to intermediate TPMT activity (heterozygous deficient or intermediate metabolizers). The TPMT*2, TPMT*3A, and TPMT*3C alleles account for about 95% of individuals with reduced levels of TPMT activity.

NUDT15 deficiency is detected in <1% of patients of European or African ancestry. Among patients of East Asian ancestry (i.e., Chinese, Japanese, Vietnamese), 2% have two loss-of-function alleles of the NUDT15 gene, and approximately 21% have one loss-of-function allele. The p.R139C variant of NUDT15 (present on the *2 and *3 alleles) is the most commonly observed, but other less common loss-of-function NUDT15 alleles have been observed.

Consider all clinical information when interpreting results from phenotypic testing used to determine the level of thiopurine nucleotides or TPMT activity in erythrocytes, since some coadministered drugs can influence measurement of TPMT activity in blood, and blood from recent transfusions will misrepresent a patient’s actual TPMT activity [see DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS].